Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients.

Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, Fujii Y.

Oncol Lett. 2010 Mar;1(2):283-287. Epub 2010 Mar 1.

2.

Clinical potential of DNA methylation in gastric cancer: a meta-analysis.

Sapari NS, Loh M, Vaithilingam A, Soong R.

PLoS One. 2012;7(4):e36275. doi: 10.1371/journal.pone.0036275. Epub 2012 Apr 27.

3.

Cigarette smoking and p16INK4α gene promoter hypermethylation in non-small cell lung carcinoma patients: a meta-analysis.

Zhang B, Zhu W, Yang P, Liu T, Jiang M, He ZN, Zhang SX, Chen WQ, Chen W.

PLoS One. 2011;6(12):e28882. doi: 10.1371/journal.pone.0028882. Epub 2011 Dec 13.

4.

DNA methylation and nonsmall cell lung cancer.

Lu F, Zhang HT.

Anat Rec (Hoboken). 2011 Nov;294(11):1787-95. doi: 10.1002/ar.21471. Epub 2011 Sep 28. Review.

5.

A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas.

Sterlacci W, Tzankov A, Veits L, Zelger B, Bihl MP, Foerster A, Augustin F, Fiegl M, Savic S.

J Thorac Oncol. 2011 Oct;6(10):1649-57. doi: 10.1097/JTO.0b013e3182295745.

6.

Global cancer statistics.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.

CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.

7.

PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.

Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J.

Int J Cancer. 2010 Apr 1;126(7):1630-9. doi: 10.1002/ijc.24896.

8.

Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers.

Yoshino M, Suzuki M, Tian L, Moriya Y, Hoshino H, Okamoto T, Yoshida S, Shibuya K, Yoshino I.

Int J Oncol. 2009 Nov;35(5):1201-9.

PMID:
19787276
9.

Prostaglandin E2 receptor 2 overexpression in squamous cell carcinoma of the lung correlates with p16INK4A methylation and an unfavorable prognosis.

Alaa M, Suzuki M, Yoshino M, Tian L, Suzuki H, Nagato K, Fujiwara T, Wada H, Moriya Y, Hoshino H, Motohashi S, Yoshida S, Shibuya K, Hiroshima K, Nakatani Y, Abdrabou A, Elkholy M, Mahfouz T, Yoshino I.

Int J Oncol. 2009 Mar;34(3):805-12.

PMID:
19212685
10.

Methylated genes as new cancer biomarkers.

Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, Sweep FC, Brunner N, Foekens JA, Schmitt M; EORTC PathoBiology Group.

Eur J Cancer. 2009 Feb;45(3):335-46. doi: 10.1016/j.ejca.2008.12.008. Epub 2009 Jan 12.

PMID:
19138839
11.

Epigenetics in cancer.

Esteller M.

N Engl J Med. 2008 Mar 13;358(11):1148-59. doi: 10.1056/NEJMra072067. Review. No abstract available.

PMID:
18337604
12.

DNA methylation markers and early recurrence in stage I lung cancer.

Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG.

N Engl J Med. 2008 Mar 13;358(11):1118-28. doi: 10.1056/NEJMoa0706550.

13.

Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.

Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M, Motoyama T.

Lung Cancer. 2007 Oct;58(1):131-8. Epub 2007 Jul 2.

PMID:
17606310
14.

Practical methods for incorporating summary time-to-event data into meta-analysis.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR.

Trials. 2007 Jun 7;8:16.

15.

Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine.

Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Manegold C, Lahm H.

Lung Cancer. 2007 Apr;56(1):115-23. Epub 2006 Dec 29.

PMID:
17196704
16.

Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer.

Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR, Wu X.

Clin Cancer Res. 2006 Dec 15;12(24):7329-38.

17.

Prognostic significance of p16(INK4a) hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis.

Ota N, Kawakami K, Okuda T, Takehara A, Hiranuma C, Oyama K, Ota Y, Oda M, Watanabe G.

Anticancer Res. 2006 Sep-Oct;26(5B):3729-32.

18.
20.

Aberrant DNA methylation of E-cadherin and p16 genes in rat lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine.

Kato A, Shimizu K, Shimoichi Y, Fujii H, Honoki K, Tsujiuchi T.

Mol Carcinog. 2006 Feb;45(2):106-11.

PMID:
16329148

Supplemental Content

Support Center